You are here: Home » News-CM » Companies » News
Business Standard

Lupin and Eli Lilly expand partnership in India

Capital Market 

to market and sell Lilly's rapid action insulin analog Lispro Eglucent

and Eli Lilly and Company (India) announced an expansion of their partnership in with the launch of Eglucent, a new brand of Lilly's rapid action insulin analog Lispro.

According to the agreement, will market and sell Eglucent through its own specialty field force while Lilly will be responsible for manufacturing and import.

Powered by Capital Market - Live News

(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)